Peter Rahmer - 28 Jul 2023 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
31 Jul 2023, 16:52:39 UTC
Prior SEC filing
28 Jun 2023
Next SEC filing
29 Sep 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Brian Adams, as attorney-in-fact

Key filing fact

Peter Rahmer filed Form 4 for Relay Therapeutics, Inc. (RLAY) on 31 Jul 2023.

Key facts

  • This page summarizes Peter Rahmer's Form 4 filing for Relay Therapeutics, Inc. (RLAY).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 31 Jul 2023, 16:52.

Change

  • Previous filing in this sequence was filed on 28 Jun 2023.
  • Current net transaction value: -$15,954.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RLAY transaction

Common Stock

Sale

Transaction value
$15,954
Shares
-1,352
Change %
-0.42%
Price
$11.80
Shares after
316,808
Date
28 Jul 2023
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on July 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

Footnote F2

Includes 284,835 shares underlying RSUs.

SEC remarks

Title: Chief Corporate Development Officer

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .